Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.

ABSTRACT: Although the past decade has seen great strides in the development of immunotherapies that reactivate the immune system against tumors, there have also been major advances in the discovery of drugs blocking oncogenic drivers of cancer growth. However, there has been very little progress in combining immunotherapies with drugs that target oncogenic driver pathways. Some of the most important oncogenes in human cancer encode RAS family proteins, although these have proven challenging to target. Recently drugs have been approved that inhibit a specific mutant form of KRAS: G12C. These have improved the treatment of patients with lung cancer harboring this mutation, but development of acquired drug resistance after initial responses has limited the impact on overall survival. Because of the im

SUBMITTER: Boumelha J 

PROVIDER: S-EPMC10722141 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature